Literature DB >> 3977452

Thin (less than or equal to 1 mm) melanomas of the extremities are biologically favorable lesions not influenced by regression.

H J Wanebo, P H Cooper, R W Hagar.   

Abstract

Although a thickness of less than or equal to 0.76 mm has been used to define biologically favorable (thin) melanoma, there is evidence that 1 mm may be a reasonable cutoff to categorize favorable extremity melanomas. This is tempered, however, by the claim that histologic regression in thin melanomas is associated with an increased metastatic rate. We have therefore addressed the following questions: Is 1 mm an appropriate cutoff point to define thin melanoma on the extremities? Does regression in a thin lesion truly signify a poor prognosis? Is the width of excision (narrow vs. wide) related to recurrence rates in these lesions? To address these issues we reviewed 48 patients with extremity melanomas, less than or equal to 1 mm in maximum thickness, treated at this institution during a 20-year period. Pathologic features included histologic type: superficial spreading (90%), nodular (6%), and not classified (4%); thickness: less than 0.76 mm (61%) and 0.76 to 1 mm (39%); and Clark's level: II (33%), III (63%), and IV (4%). A moderate or marked lymphoid infiltrate occurred in 75%, and histologic tumor regression was found in 50%. The median margin of excision, as stated by the surgeon, was 4 cm. The median margin measured by the pathologist in unfixed specimens was 3.5 cm. Although 13% had atypical melanocytic hyperplasia in the initial excisional biopsy margin, all reexcisions were clear. Of 21 patients having node dissections, none had nodal metastases. There were no recurrences or deaths due to melanoma (median follow-up: 90 months). We conclude that melanomas less than or equal to 1 mm in thickness on the extremities can be defined as biologically highly favorable, "thin" lesions. Foci of regression do not alter their behavior. Their favorable prognosis justifies conservative excision in most cases.

Entities:  

Mesh:

Year:  1985        PMID: 3977452      PMCID: PMC1250740          DOI: 10.1097/00000658-198504000-00016

Source DB:  PubMed          Journal:  Ann Surg        ISSN: 0003-4932            Impact factor:   12.969


  24 in total

1.  Tumor thickness and lymphocytic infiltration in malignant melanoma of the head and neck.

Authors:  M G Hansen; A B McCarten
Journal:  Am J Surg       Date:  1974-10       Impact factor: 2.565

2.  Spontaneous regression of primary malignant melanomas with regional metastases.

Authors:  J L Smith; J S Stehlin
Journal:  Cancer       Date:  1965-11       Impact factor: 6.860

3.  Tumor thickness as a guide to surgical management of clinical stage I melanoma patients.

Authors:  C M Balch; T M Murad; S J Soong; A L Ingalls; P C Richards; W A Maddox
Journal:  Cancer       Date:  1979-03       Impact factor: 6.860

4.  Tumor thickness, level of invasion and node dissection in stage I cutaneous melanoma.

Authors:  A Breslow
Journal:  Ann Surg       Date:  1975-11       Impact factor: 12.969

5.  Prognostic significance of the histological features of malignant melanoma.

Authors:  V J McGovern; H M Shaw; G W Milton; G A Farago
Journal:  Histopathology       Date:  1979-09       Impact factor: 5.087

6.  Malignant melanoma of the extremities: a clinicopathologic study using levels of invasion (microstage).

Authors:  H J Wanebo; J Woodruff; J G Fortner
Journal:  Cancer       Date:  1975-03       Impact factor: 6.860

7.  On the prognostic importance of white depressed areas in the primary lesion of superficial spreading melanoma.

Authors:  D I McLean; R A Lew; A J Sober; M C Mihm; T B Fitzpatrick
Journal:  Cancer       Date:  1979-01       Impact factor: 6.860

8.  Conservative surgical management of superficially invasive cutaneous melanoma.

Authors:  A B Cosimi; A J Sober; M C Mihm; T B Fitzpatrick
Journal:  Cancer       Date:  1984-03-15       Impact factor: 6.860

9.  The regressing thin malignant melanoma: a distinctive lesion with metastatic potential.

Authors:  M A Gromet; W L Epstein; M S Blois
Journal:  Cancer       Date:  1978-11       Impact factor: 6.860

10.  A multifactorial analysis of melanoma. II. Prognostic factors in patients with stage I (localized) melanoma.

Authors:  C M Balch; S J Soong; T M Murad; A L Ingalls; W A Maddox
Journal:  Surgery       Date:  1979-08       Impact factor: 3.982

View more
  5 in total

1.  The significance of inflammation and regression in melanoma.

Authors:  M G Cook
Journal:  Virchows Arch A Pathol Anat Histopathol       Date:  1992

2.  Regression in primary cutaneous melanoma: etiopathogenesis and clinical significance.

Authors:  Phyu P Aung; Priyadharsini Nagarajan; Victor G Prieto
Journal:  Lab Invest       Date:  2017-02-27       Impact factor: 5.662

3.  Outcome of sentinel lymph node biopsy and prognostic implications of regression in thin malignant melanoma.

Authors:  Susannah E McClain; Amber L Shada; Megan Barry; James W Patterson; Craig L Slingluff
Journal:  Melanoma Res       Date:  2012-08       Impact factor: 3.599

4.  Cutaneous melanomas exhibiting unusual biologic behavior.

Authors:  H M Shaw; J K Rivers; S W McCarthy; W H McCarthy
Journal:  World J Surg       Date:  1992 Mar-Apr       Impact factor: 3.352

5.  Biology of human cutaneous melanoma.

Authors:  Elias G Elias; Joanne H Hasskamp; Bhuvnesh K Sharma
Journal:  Cancers (Basel)       Date:  2010-03-12       Impact factor: 6.639

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.